Watch stocks you care about
The single, easiest way to keep track of all the stocks that matter...
Your own personalized stock watchlist!
It's a 100% FREE Motley Fool service...
While the federal government now gets to deal with "massive" budget cuts of around 2.3% of total annual federal spending put into law by President Obama and Congress, some investors are left wishing they could be so lucky after the past week. Here are three horrendous health-care stocks for the week with losses that make the levels of sequestration cuts sound like a great deal.
No help for Heplisav
Shares of Dynavax (NASDAQ: DVAX ) plunged 33% this week after the Food and Drug Administration rejected approval for hepatitis B vaccine Heplisav. This wasn't really a huge surprise, though, since the FDA's advisory committee recommended against approval back in November.
The roadblock relates primarily to safety of the vaccine. Dynavax announced that the FDA's response indicated that further evaluation was needed to evaluate safety and that it had concerns that Heplisav could cause rare autoimmune diseases. The agency also needed additional information about the quality control processes for manufacturing the vaccine.
Is Dynavax now dead in the water? Maybe not. The company stated that the FDA "indicated its willingness to continue discussions regarding a more restricted use of Heplisav." Dynavax thinks that it might be able to move forward with a more restricted approval of the drug, perhaps limited to adults over age 40 or patients with chronic kidney disease, without addidtional clinical studies.
No hurry, much worry
Accretive Health (NASDAQOTH: ACHI ) announced this week that it was postponing the release of its fourth-quarter and full-year financial results. The market fretted over the delay, sending shares down 23% for the week.
The company explained the reason for the postponement was that it needed to evaluate how revenue is recognized for revenue cycle management agreements. Accretive didn't think that total revenue would be affected, but the timing in which the revenue was recognized might be.
If adjustments aren't too extensive, Accretive Health should recover over time from this week's meltdown. You have to wonder, though, how a company that is in the business of managing revenue cycles for its customers can mess up its own revenue. Accretive's competitors will probably raise that very question for quite a while.
Waiting for weight pill success
Investors in VIVUS (NASDAQ: VVUS ) will have to wait longer for a turnaround in the stock's decline. Shares fell 18% this week, adding to a long slide that began last summer.
VIVUS released its fourth-quarter results on Monday. Unfortunately for its shareholders, those results weren't too great. VIVUS lost $0.56 per share, worse than the consensus analyst estimates of $0.44 per share. Analysts were expecting revenue to be around $4 million, but actual revenue came in far lower at $2 million.
Sales for the company's weight loss pill, Qsysmia, haven't taken off as hoped for. One of the key problems thus far has been VIVUS' sales channel, which is currently limited to mail-order pharmacies. There have been some reimbursement hurdles as well, although insurer Aetna (NYSE: AET ) and pharmacy benefits manager Express Scripts (NASDAQ: ESRX ) both have announced they would cover Qsymia.
Which of the three horrendous stocks of the past week should definitely be sequestered from investors' portfolios? I'd have to go with Dynavax as the one facing the toughest battle.
Accretive's problems are self-inflected, and VIVUS does at least have two products already approved by the FDA. Dynavax faces challenges in large part beyond its control. That's not to way that Dynavax doesn't have the possibility of coming back. It does. But, like our bloated federal government, we have to cut somewhere.
Is now the time to sell VIVUS?
VIVUS' shares were clobbered after Qsymia's dismal launch. Investors everywhere are wondering whether the tide will turn for this fledgling drugmaker or if now is the perfect time to sell. In a new premium research report, the Fool's top health care contributor breaks down this complex story and explains the details VIVUS investors must know -- including reasons to buy and sell. To find out more about this premium report -- complete with a full year of free updates -- click here now.